{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05557708",
            "orgStudyIdInfo": {
                "id": "202209363"
            },
            "organization": {
                "fullName": "University of Iowa",
                "class": "OTHER"
            },
            "briefTitle": "A Safety Study of 212Pb-Pentixather Radioligand Therapy",
            "officialTitle": "Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-safety-study-of-pentixather-radioligand-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-20",
            "studyFirstSubmitQcDate": "2022-09-23",
            "studyFirstPostDateStruct": {
                "date": "2022-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Yusuf Menda",
                "investigatorTitle": "Professor and Director, Nuclear Medicine",
                "investigatorAffiliation": "University of Iowa"
            },
            "leadSponsor": {
                "name": "Yusuf Menda",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                },
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                },
                {
                    "name": "Holden Comprehensive Cancer Center",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.",
            "detailedDescription": "This is a study to determine what dose is acceptably safe for further testing.\n\nIn this study, participants are asked to:\n\n* undergo SPECT/CT imaging with Lead-203 Pentixather (a radiotracer) to ensure the tumor lesions have the needed receptors\n* undergo serial blood sampling for during and after the SPECT/CT scan for radiation and dosimetry calculations (to determine how much of the Lead-212 Pentixather to administer)\n* receive up to 2 infusions of arginine \\& lysine as a kidney protectant\n* receive up to 2 infusions of Lead-212 Pentixather, 6 weeks between each infusion\n* undergo imaging at 3 months post treatment to determine disease response"
        },
        "conditionsModule": {
            "conditions": [
                "Carcinoid Tumor Lung",
                "Neuroendocrine Tumor of the Lung",
                "Carcinoma, Small-Cell Lung"
            ],
            "keywords": [
                "radioligand therapy",
                "pentixather",
                "Lead 203",
                "Lead 212",
                "alpha therapy",
                "dosimetry"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "212-Lead Pentixather",
                    "type": "EXPERIMENTAL",
                    "description": "Single intravenous infusion of Pentixather radiolabeled with Lead-212. Administered activity to participant is calculated from bone marrow and renal radiation constraints.\n\nTreatment is administered in 2 cycles with 6 weeks between the cycles.",
                    "interventionNames": [
                        "Drug: 212-Lead Pentixather",
                        "Diagnostic Test: 203-Lead Pentixather SPECT/CT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "212-Lead Pentixather",
                    "description": "Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.",
                    "armGroupLabels": [
                        "212-Lead Pentixather"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "203-Lead Pentixather SPECT/CT",
                    "description": "Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.",
                    "armGroupLabels": [
                        "212-Lead Pentixather"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine the recommended phase 2 dose of 212-Lead Pentixather",
                    "description": "The recommended phase 2 dose is based on the number of dose limiting toxicities observed post-treatment.",
                    "timeFrame": "3 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine the targeting of atypical pulmonary neuroendocrine tumor and/or neuroendocrine carcinoma lesions with 203-Lead Pentixather SPECT/CT",
                    "description": "The number of lesions identified with 203-Lead Pentixather SPECT/CT will compared to FDG PET/CT and diagnostic CT scans at baseline.",
                    "timeFrame": "baseline"
                },
                {
                    "measure": "Determine tumor response",
                    "description": "Tumor response will be assessed using the Response Evaluation Criteria in Solid Tumours (RECIST, v 1.1).",
                    "timeFrame": "3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* ability to provide independent consent\n* adequate bone marrow function (platelet count \u2265 100,000; hemoglobin of \u2265 10 g/dL; neutrophil count \u2265 1,500 cells/mm3)\n* adequate kidney function (creatinine clearance of \u2265 50 mL/min using the Cockcroft-Gault equation\n* adequate liver function (serum bilirubin \u2264 3x the upper limit of normal, AST \u2264 5x the upper limit of normal, and ALT \u2264 5x the upper limit of normal)\n* failed initial therapy or declined further therapy known to confer benefit\n* have at least one lesion \u2265 2 cm that is positive for CXCR4 as demonstrated by Lead-203 Pentixather SPECT/CT\n\nExclusion Criteria:\n\n* major surgery within 4 weeks of consent\n* antoher investigational agent within 4 weeks of consent\n* uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements.\n* prior solid organ transplant\n* cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas)\n* antibody therapy within the 21 days of consent\n* allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent\n* pregnancy\n* breastfeeding\n* refusal to comply with birth control requirements during study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yusuf Menda, MD",
                    "role": "CONTACT",
                    "phone": "319-356-3214",
                    "email": "yusuf-menda@uiowa.edu"
                },
                {
                    "name": "Kellie Bodeker, Ph.D.",
                    "role": "CONTACT",
                    "phone": "319-384-9425",
                    "email": "kellie-bodeker@uiowa.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Yusuf Menda, MD",
                    "affiliation": "University of Iowa",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Iowa Theranostics Center",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yusuf Menda, MD",
                            "role": "CONTACT",
                            "phone": "319-356-3214",
                            "email": "yusuf-menda@uiowa.edu"
                        },
                        {
                            "name": "Kristin Gaimari-Varner, RN",
                            "role": "CONTACT",
                            "email": "kristin-gaimari-varner@uiowa.edu"
                        },
                        {
                            "name": "Yusuf Menda, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Stephen Graves, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Chandrikha Chandrasekharan, MBBS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Joseph Dillon, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David Bushnell, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Michael Graham, MD, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Janet Pollard, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "28744319",
                    "type": "BACKGROUND",
                    "citation": "Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hanscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ. [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics. 2017 Jun 11;7(9):2350-2362. doi: 10.7150/thno.19119. eCollection 2017."
                },
                {
                    "pmid": "35674738",
                    "type": "BACKGROUND",
                    "citation": "Buck AK, Serfling SE, Lindner T, Hanscheid H, Schirbel A, Hahner S, Fassnacht M, Einsele H, Werner RA. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. doi: 10.1007/s00259-022-05849-y. Epub 2022 Jun 8."
                },
                {
                    "pmid": "35312939",
                    "type": "BACKGROUND",
                    "citation": "Serfling SE, Lapa C, Dreher N, Hartrampf PE, Rowe SP, Higuchi T, Schirbel A, Weich A, Hahner S, Fassnacht M, Buck AK, Werner RA. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. Mol Imaging Biol. 2022 Aug;24(4):659-665. doi: 10.1007/s11307-022-01717-1. Epub 2022 Mar 21."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Data are obtained from protected health information. Only data from study participants who consented to data sharing will be shared.\n\nData type:\n\n* patient demographics (age at consent, self-identified race ethnicity and gender, insurance status)\n* tumor response (RECIST measures, imaging DICOM)\n* adverse event logs indicating CTCAEv5 term and severity on a per-subject basis\n* dosimetric analysis of 203-Lead Pentixather scans\n* dose limiting toxicities: type and incidence\n* diagnostic analysis of 203-Lead Pentixather and FDG PET/CT (or CT) scans",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "Protocol and ICF are made available upon request by email. All documents (Protocol, ICF, SAP, CSR, and analytic code) will be made available after primary objective is completed.",
            "accessCriteria": "A materials transfer agreement or data usage agreement (depending upon the legal department's preference) will need to be fully executed prior to sharing."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000002276",
                    "term": "Carcinoid Tumor"
                },
                {
                    "id": "D000018288",
                    "term": "Carcinoma, Small Cell"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Tumors of the Lung",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "asFound": "Neuroendocrine Tumors",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20423",
                    "name": "Carcinoma, Neuroendocrine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20433",
                    "name": "Carcinoma, Small Cell",
                    "asFound": "Carcinoma, Small Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5533",
                    "name": "Carcinoid Tumor",
                    "asFound": "Carcinoid Tumor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Carcinoma, Small Cell Lung",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "asFound": "Neuroendocrine Tumors",
                    "relevance": "HIGH"
                },
                {
                    "id": "T948",
                    "name": "Carcinoid Tumor",
                    "asFound": "Carcinoid Tumor",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Carcinoma, Small Cell Lung",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}